Angiotensin II Signaling and Fear Extinction: Translational Evidence and Novel Receptor Targets

Daniel M. Stout and Victoria B. Risbrough

There is an alarming paucity of new clinical studies for novel treatments for fear-based disorders and in particular post-traumatic stress disorder (PTSD). In the last 2 decades there has been a paradigm shift in exploring pharmacotherapeutics that are not simply static anxiolytics to be taken daily for symptom alleviation but that might instead act at key mechanisms of recovery like fear extinction. Such compounds may enhance natural extinction or be used specifically as adjunctive treatments for extinction-based therapies (e.g., exposure therapy). These treatments are targeted to signaling pathways that modulate fear expression and extinction circuits to facilitate rapid and long-lasting symptom remission (1). Multiple treatments that have been tested in animals and humans increase extinction learning and/or retention, including those that act at glutamatergic, glucocorticoid, oxytocin, dopamine, norepinephrine, and endocannabinoid receptor targets. Although some remain promising in translation to extinction-based therapy, limitations have arisen (e.g., potential enhancement of reconsolidation of fear memory, inconsistent effects, or potential side effects), underscoring the need to test alternative targets, in particular repurposed drugs that have good safety profiles in the trauma-exposed populations. Two studies in this issue of *Biological Psychiatry* (2,3) provide new evidence for angiotensin II (Ang-II) receptors 1 and 2 (AT\(_1\)R and AT\(_2\)R) as potential novel targets for this approach (4).

AT\(_1\)R and AT\(_2\)R are G protein–coupled receptors that are activated by Ang-II to modulate cardiovascular, inflammatory, and stress systems (5). AT\(_1\)R and AT\(_2\)R are located peripherally and in the central nervous system, including the fear network [i.e., the amygdala, the hippocampus, and the prefrontal cortex (PFC)] (6) (Figure 1). Ang-II signaling blockers, including angiotensin-converting enzyme inhibitors and the AT\(_1\)R antagonist losartan, are commonly prescribed for hypertension and are safe medications with few reported side effects. Previous epidemiological analyses identified an intriguing association between PTSD and angiotensin-converting enzyme inhibitors and losartan in patients with hypertension. Patients taking these medications had fewer PTSD symptoms than patients taking other hypertension medications, prompting an examination of Ang-II and AT\(_1\)R signaling contributions to PTSD-related functions (7,8). Given the diverse signaling capabilities of AT\(_1\)R, the mechanism for potential PTSD symptom amelioration was unclear. Preclinical studies in mice suggested that losartan associations with reduced PTSD symptoms may be via enhancement of fear extinction, with systemic losartan treatment enhancing extinction learning and retention (9). Notably, losartan effects on extinction were observed even with long-term treatment, suggesting that tolerance does not develop to these proextinction effects. Later studies suggested that these effects could be through the blockade of AT\(_1\)R at corticotropin-releasing factor cell types, as AT\(_1\)R gene deletion in corticotropin-releasing factor cells mimics the extinction enhancement observed with losartan treatment (10). These studies also reported relative selectivity of AT\(_1\)R effects for fear extinction without affecting fear learning, suggesting that this receptor may be a compelling target for adjunctive exposure therapy because it can mitigate any potential “side effects” of treatment on reconsolidation or new fear associations during treatment. However, it was not known if these effects on extinction mechanisms translated to humans.

Zhou et al. (3) tested whether losartan improves extinction learning in humans and examined its effects on fear circuit function. In a randomized, placebo-controlled design, 70 healthy men received a single dose of losartan (50 mg) or a placebo after completing a fear conditioning task. After 90 minutes, participants completed extinction learning during skin conductance response and functional magnetic resonance imaging recording. Consistent with the findings in rodents, losartan treatment improved early extinction learning compared with placebo as measured by reduced skin conductance response and increased ventromedial PFC (vmPFC) activity during early extinction. Mediation analysis suggested that losartan effects on extinction of skin conductance response to the conditioned stimulus (CS+) were mediated by increased vmPFC activity. Losartan also increased functional connectivity between the vmPFC and the basolateral amygdala. These data support the translation of Ang-II signaling pathways in extinction across species and suggest that losartan treatment could be boosting vmPFC-amygdala circuit activity to enhance fear inhibition. Given that the treatment was systemic, however, the circuit mechanism, i.e., the critical node of AT\(_1\)R signaling blockade for extinction effects, is still unclear and should be addressed in further animal studies (see below). The next critical steps in humans are to determine if losartan treatment enhances long-term extinction retention and to subsequently test its efficacy to improve fear-based symptoms and response to exposure-based therapies.

Another important signaling pathway for the Ang-II system is the AT\(_2\)R, which can functionally oppose many AT1R signaling effects (5,6). Like AT\(_1\)R, AT\(_2\)R is detected across multiple regions of the fear circuit; however, its contribution to learned fear processes had not yet been described. Yu et al. (2)
fill this gap with their report on the molecular and functional profile of AT2R signaling in the amygdala and its role in fear extinction. AT2R agonist C21 infusions into the central nucleus of the amygdala (CeA) before extinction learning decreased freezing during extinction to both contextual and discrete fear cues. The decrease in freezing persisted 24 hours later for contextual cues, and corticosterone response to re-exposure to threat-related context was also diminished by C21 treatment, suggesting that AT2R activation reduces both hormonal and behavioral responses to learned fear cues and facilitates extinction. Locomotor and anxiety-like behavior were unaffected by C21 treatment, indicating a relatively specific effect of AT2R activation on learned fear behavior. To probe the potential mechanism for AT2R to reduce learned fear, Yu et al. (2) examined the role of specific AT2R cell types and projections using retrograde labeling, showing that AT2R cells in the CeA include gamma-aminobutyric acidergic neurons that project to the periaqueductal gray (PAG), a midbrain region controlling defensive responses to threat. These projections are a likely contributor to AT2R signaling effects on learned fear. However, AT2R is also detected in other regions of the fear circuit (Figure 1), indicating that the amygdala may not be the only player in fear circuit functions that could be modulated by AT2R signaling. Collectively, these results provide important new insights regarding how Ang-II receptors beyond AT1R modulate fear expression and extinction, opening the door for investigating the Ang-II signaling system more broadly in relation to regulating fear memories and as a target for fear disorders.

These studies prompt many more questions about the underlying circuit and signaling mechanisms through which ATRs have their functional effects on fear expression and extinction. AT1R is expressed throughout the majority of the key nodes of the fear extinction circuit including the
amygdala, the PFC (e.g., infralimbic and prelimbic cortex), and the hippocampus, as well as downstream regions that regulate hormonal and behavioral output of learned fear responses (e.g., the paraventricular nucleus of the hypothalamus and the PAG). AT2R is densely expressed in the amygdala and the PFC, and possibly the hippocampus. Therefore, AT1R and AT2R activation could be an important fine-tuning mechanism for learned fear expression and extinction across many of these connections. For example, the infralimbic cortex has bidirectional connections with the amygdala and an indirect inhibitory pathway to the medial division of the CeA via the intercalated cells (Figure 1). Therefore, AT2R blockade or AT2R activation in the infralimbic cortex may potentially facilitate inhibitory learning and the inhibition of fear expression via the amygdala, which is consistent with the effects of losartan on vmPFC activity reported by Zhou et al. (3). Another possibility is that Ang-II modulation of fear expression is via circuits downstream of the amygdala that control both hormonal and behavioral output of fear expression (e.g., paraventricular nucleus of the hypothalamus and the PAG), consistent with the findings of Yu et al. (2). The pharmacology of AT1R and AT2R is also fascinating and complex. AT1R and AT2R can recruit multiple heterotrimeric G proteins, and both are expressed at the cellular, mitochondrial, and nuclear membrane in neurons (6). AT1R and AT2R form heterodimers with each other, which reduces AT1R signaling efficacy (6). Therefore, AT2R signaling effects that functionally oppose AT1R signaling on fear extinction could be via multiple possible mechanisms, including modulation of competing circuits (e.g., enhance CeA gamma-aminobutyric acidergic signaling to the PAG) and/or potentially through opposing signaling and/or heterodimerization if expressed in the same cell. Understanding the mechanisms underlying AT1R and AT2R opposing functional effects on fear expression and extinction is an exciting avenue for future research.

From a clinical perspective, the growing body of clinical and preclinical research on Ang-II modulation of extinction provides a mechanistic framework for characterizing the therapeutic benefit of Ang-II for fear-based disorders such as PTSD. A multisite randomized control trial of losartan as a stand-alone treatment for PTSD is currently underway and will be revealing with regard to determining the overall clinical efficacy of Ang-II modulation on PTSD symptoms (study details at https://clinicaltrials.gov/ct2/show/NCT02709018). However, this study does not directly examine if losartan treatment affects extinction phenotypes in these patients (7,8). The findings by Zhou et al. (3) and Yu et al. (2) of translatability and novel ATR targets support further examination of Ang-II modulators to modify extinction and as potential adjunctive treatments with exposure therapy. Addressing the remaining questions raised by these studies will be important for understanding the mechanisms that confer risk for fear-based disorders like PTSD, for optimizing interventions, and for clarifying the biological bases for the role of Ang-II in fear extinction enhancement.

Acknowledgments and Disclosures
This work was supported by the Center of Excellence for Stress and Mental Health, Veterans Affairs San Diego Healthcare System, Veterans Affairs Career Development Award IK2-CX001861 (to DMS), and by Veterans Af- fairs Grant No. BX004312, Department of Defense Grant No. W81XWH-17-1, National Institute on Alcohol Abuse and Alcoholism Grant No. R01AA026560-03, and National Institute of Mental Health Grant No. P50MH098889 (to VBR). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Depart- ment of Veterans Affairs or the United States government. We thank Susan Powell for her helpful comments. The authors report no biomedical financial interests or potential conflicts of interest.

Article Information
From the Center of Excellence for Stress and Mental Health, Veterans Affairs San Diego Healthcare System, and the Department of Psychiatry, University of California San Diego, San Diego, California. Address correspondence to Victoria B. Risbrough, Ph.D., Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, Mail Code 0804, La Jolla, CA 92093-0804; E-mail: vrisbrough@ucsd.edu. Received Sep 24, 2019; accepted Sep 24, 2019.

References